From: Seeking Alpha | BCRX Message Board Posts


BioCryst Pharmaceuticals Inc.

  BCRX website

BCRX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  12774 of 12785  at  9/13/2021 9:35:57 PM  by

frnktofini


From: Seeking Alpha

 

Conclusion

While it is possible for any biotech company to suffer failure of a drug trial or other unforeseen disappointments leading to share depreciation, BioCryst has proven they know how to get FDA approvals and bring drugs to the market. I have been covering BCRX since October 27 when it was trading at $3.73 a share. It was cheap then but nowhere near as cheap as it is now. The eventual approval of Oral Factor D for PNH makes this stock worth at least $100 a share. Alexion was bought for $39 billion with far inferior results than BioCryst produced in the 9930 phase 1 PNH trial. There are at least 10 other rare drug indications BioCryst could directly enter phase 2-3 trials. Safety trials should no longer be needed. The opportunity to possibly invest in an early-stage Regeneron (REGN) should be priceless. The opportunity to buy this stock at reasonable valuations is ending. The third quarter is ending in 3 weeks. Another massive earnings beat and the beginning of the pivotal PNH trials will send BCRX to new levels. The ease of burden for treatment will win every time. Twenty million shares short are soon to figure out there is no way out of this position until you can find 20 million shares for sale.



     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 4  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
12775 Re: From: Seeking Alpha capecod3 0 9/15/2021 3:00:16 PM


Financial Market Data provided by
.
Loading...